ArticleKidney international reports2025
Biopsy-Based Transcriptomics Support Rejection Monitoring Through Repeated Kidney Allograft Biopsies.
Article in Kidney international reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Biopsy-based Transcriptomics in Banff 2022 Antibody Mediated Rejection Categories.Kidney international reports · 2026Article
- Antibody-mediated rejection in ABO-incompatible kidney transplantation.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- Rejection-Focused Precision Medicine in Kidney Transplantation: Biology, Biomarkers, and Artificial Intelligence.Life (Basel, Switzerland) · 2026Review
- The Evolution of Molecular Phenotypes Through Time in Kidney Transplant Recipients.Transplantation direct · 2026Article
- Steroid pulse therapy for acute T-cell-mediated rejection after kidney transplantation: mechanisms, evidence, and unresolved questions.Frontiers in immunology · 2026Review
- Novel Biomarkers for Rejection in Kidney Transplantation: A Comprehensive Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Biopsy-based transcriptomics may detect subthreshold signals suspicious for rejection in histologically "rejection-free" biopsies, reflect antirejection treatment responses, and indicate gradual phenotyping of rejection in kidney allograft biopsies. Methods: We investigated 80 "biopsy series" (baseline and corresponding follow-up biopsies) from 2018 to 2025, assessed by histopathology (Banff classification) and the Molecular Microscope Diagnostic System (MMDx). Results: Baseline biopsies showed histological rejection, including partial antibody-mediated rejection (AMR) and borderline T-cell-mediated rejection (TCMR) in 55 of 80 cases (69%), with 55% molecular rejection confirmation. After a median of 9 months (interquartile range: 4-18), follow-up biopsies detected histological rejection in 9 of 25 (36%) previously "rejection-free" cases. Corresponding baseline biopsies had higher rejection (Rejection Conclusions: Biopsy-based transcriptomics differentiated suspicious molecular signals among histologically "rejection-free" biopsies progressing to rejection and provided a monitoring tool after antirejection treatment interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.